Free Shipping on All Orders $75 Or More!

Your Trusted Brand for Over 35 Years

Health Protocols

Prostate Cancer Prevention

Prostate Diagnostic and Assessment Tests

There are now a number of diagnostic tests to identify early stage prostate cancer and then monitor the success or failure of a wide range of treatment options.  

This section succinctly describes conventional prostate gland diagnostic tests along with those that mainstream medicine often overlooks, to the detriment of their patients. All of these tests, however, are commercially available.


PSA (Prostate-Specific Antigen)

Perhaps the greatest breakthrough in the detection and management of prostate cancer was the approval of the prostate-specific antigen (PSA) blood test in 1986, but it was only approved for men already diag­nosed with prostate cancer (NCI 2012). It wasn’t until 1994 that the FDA approved the PSA test as a prostate cancer screening test for all men (NCI 2012). Prostate-specific antigen is a protein produced by the cells of the prostate gland, including both cancerous cells as well as cells that are benign (NCI 2012). Since very little PSA escapes into the blood­stream from a healthy prostate, an elevated PSA level in the blood indicates an abnormal condition of the prostate gland—which can be either benign or malig­nant. PSA test results can be used both to detect poten­tial prostate problems and to follow the progress of prostate cancer therapy (NCI 2012).

Because tumor growth is essentially exponential, with one cell dividing into two, two to four, four to eight, and so on, a tumor cell product such as PSA can reflect such exponential growth—measuring the time it takes for PSA to double (PSA doubling time, or PSADT) (Strum 2005). Also, the PSA rate of rise (PSA velocity), although not a more specific marker, may have value in prostate cancer prognosis—because men with pros­tate cancer whose PSA level increased by more than 2.0 ng/mL during the year before their diagnosis showed a higher risk of death from prostate cancer (D’Amico 2004). Additionally, though not an absolute criteria for or against malignancy, PSA velocity can serve as a gauge regarding the likelihood of a malignant condition (Strum 2005). A rising PSA velocity in excess of .75 ng/mL/year relates to an increased probability of a malignant condition (Strum 2005).

The reference interval provided by most conven­tional laboratories for the PSA test is 0.00-4.00 nano­grams per milliliter (ng/mL) (LabCorp 2013a). Conventional reference ranges suggest that PSA levels under 4.0 ng/mL are normal, but any reading over 2.0 ng/mL can indicate unhealthy activity, such as prostatitis, benign prostate hypertrophy, or prostate cancer (Strum 2005). If PSA readings begin to elevate, there are interventions that can reduce or stabilize the production of PSA, shutting down a mechanism used by cancer cells to escape their con­finement within the prostate gland (Webber 1995). PSA readings can increase immediately after ejaculation, returning slowly to baseline levels within 24-48 hours (Tchetgen 1996; Herschman 1997).

Chart of PSA Ranges with Succinct Suggestions

PSA (ng/mL)

Concise Recommendation




Initiate measures to support prostate health and have digital rectal exam performed


Moderate concern–assess PSA velocity—have digital rectal exam—consider other tests.


Too high—additional diagnostics recommended

Free PSA

Free PSA is a newer evaluation for prostate health. Most PSA in the blood is bound to serum proteins, but a small amount is not protein-bound and is called free PSA (Strum 2005; Gion 1997). In men with prostate cancer, the ratio of free (unbound) PSA to total PSA is decreased (Strum 2005). The free PSA test measures the percentage of free PSA relative to the total amount (Abrahamsson 1997). The lower the ratio, the greater the probability of prostate cancer. Measuring free PSA may help eliminate unnecessary biopsies (Gion 1997). Free PSA readings increase immediately after ejacula­tion, returning slowly to baseline levels within about 24 hours (Tchetgen 1996). Although not used as an initial screening test, a lower percentage of free PSA might mean your doctor needs to do a further workup.

Below are the percentage of PSA ranges and what they represent as far as prostate cancer risk. Note that when the percentage of free PSA is high (over 20%), this means the risk of prostate cancer is low, whereas a low percentage of free PSA (under 11% indicates high risk).


Free PSA%

50-64 Years

65-75 Years













Over 25%



PCA3 Urine

PCA3 is a molecular diagnostic test performed on urine rather than blood and detects mRNA that is excreted into the urethra via the epithelial cells that line the prostatic ducts (Hessels 2009). Prostate cancer cells tend to produce this compound far more than normal cells do (Hessels 2009). The PCA3 urine test has to be done in a urolo­gist’s, or other doctor’s, office, because it requires a digital rectal massage just prior to collection of the urine (Day 2011).

PCA3 testing is most useful when repeated over a period of time to monitor for changes in the observed value. In general, a PCA3 score of 35 is considered the optimal cut-off. A score of greater than 35 reflects an increased probability of a positive biopsy. A score of less than 35 reflects a decreased probability of a positive biopsy.

25-Hydroxy Vitamin D

Research points to a connection between vitamin D levels and cancer (Qin 2013; van den Bemd 2002). Experimental studies indicate that low levels of vitamin D increase prostate cancer risk (Lou 2004). And further evidence shows that the active form of vitamin D promotes differentiation and inhibits proliferation, invasiveness, and metastasis of human prostate cancer cells (Lou 2004; John 2005). Detecting deficient levels allows you and your physician to implement vitamin D supplementation to help avert illnesses associated with inadequate vitamin D levels. For this nutrient, individualized dosing is of particular importance, and the only way to accomplish this is through vitamin D blood testing. Although conventional laboratory refer­ence ranges list a reference interval of 30-100 ng/mL, Life Extension supports maintaining vitamin D in the 50-80 ng/mL range (LabCorp 2013b).


Prolactin, a peptide hormone largely secreted by the anterior pituitary gland, has typically remained restricted to the fields of lactation and infertility. However, researchers discovered that prolactin plays a major role in the differentiation and development of the prostate gland (Sethi 2012). Both malignant and healthy prostates produce prolactin. Prostatic fluids from patients with cancer also have higher prolactin levels than controls (Sethi 2012). In vitro, prolactin induces prolifera­tion and antagonizes apoptosis in prostate organ cul­ture and in some tumor cell lines (Sethi 2012). Increased levels of prolactin have significant stimulatory action on the prostate and on prostate ductal development and may lead to hyperplastic growth, independent of elevations in circulating androgen levels (Kindblom 2003).

Labcorp normal reference range - Male: 4.0-15.2 ng/mL

Optimal for Prostate Cancer- <5 ng/mL

What You Need to Know

Methods of Diagnosing and Assessing Prostate Cancer

  • Prostate cancer remains unique in that there are many tests to identify early stage disease and then monitor the success or failure of a wide range of treatment options.
  • Perhaps the greatest breakthrough in the detection and management of prostate cancer was the approval of the prostate-specific antigen (PSA) blood test.
  • Experimental studies indicate that low levels of vitamin D increase prostate cancer risk.
  • Men can easily be tested for palpable prostate abnormalities with a digital rectal exam (DRE), a simple test that provides a lot of information.
  • A comprehensive blood test for specific hormone levels is useful since many hormones have been shown to play a role in the proliferation of prostate cancer.
  • Combining imaging tests such as ultrasound, MRI, QCT, Color Doppler, and bone scan can give the most complete picture, allowing for full physical and architectural assessment of tumors, including those that have spread beyond the prostate.

DRE (Digital Rectal Exam)

Men can easily be tested for palpable prostate abnormalities with a digital rectal exam (DRE), a sim­ple test that provides a lot of information (Tisman 2001). It gives the physician a sense of the prostate gland volume. The bigger the prostate, the more PSA the gland is entitled to make without indicating a potential problem. A basic rule is that the prostate gland volume multiplied by the amount of PSA produced per unit of volume in benign prostate tissue is 0.067 ng (Tisman 2001). This means that a 50-year old man with a normal size prostate of 30 grams (or cubic centimeters) would therefore be entitled to make approximately 2 ng of PSA. If such a man has a PSA of 4.0 ng/mL, it would indicate an excess of about 2 ng of PSA and the need for further investigation to rule out prostate cancer.

In addition to estimating prostate gland volume and calculating the benign cellular contribution to the total PSA value, the DRE can also aid in finding hard nodules or other evidence of disease. Palpable (able to be felt) abnormalities of the prostate gland relate to tumor volume, also called tumor burden (Tisman 2001). In the years before routine testing with PSA, most prostate cancers were already palpable via DRE by the time of diagnosis. Today, close to 70% of prostate cancers newly diagnosed in the US are no longer associated with palpable disease (Tisman 2001). This shows the value of PSA screening in allowing an earlier diagnosis of pros­tate cancer — before the cancer has had a chance to get bulkier and manifest itself as a palpable disease, known as a T2 disease. Most American men when first diagnosed with prostate cancer have non-palpable, or T1, prostate cancer (Tisman 2001).

Blood Hormone Profile

A comprehensive blood test for specific hormone levels is useful. In addition to the free and total tes­tosterone levels covered earlier, a complete blood test should include levels of estradiol, DHT (dihydrotestos­terone), pregnenolone, DHEA-S (dehydroepiandros­terone sulfate), FSH (follicle-stimulating hormone), LH (luteinizing hormone), and possibly, IGF-1 (insu­lin-like growth factor 1). DHT plays a role in the development and exacerbation of benign prostatic hyperplasia, as well as prostate cancer (NCI 2013c). FSH (follicle-stimulating hormone) and LH (luteinizing hormone) regulate the reproductive processes of the body, and in aging men, a rise in FSH and LH can be indicative of andropause (Dandona 2010; Miwa 2006). Studies have shown that increased levels of IGF promote cancer growth and confer resis­tance to conventional treatments (chemotherapy and radiation) (Arnaldez 2012; Kojima 2009).

PAP (Prostatic Acid Phosphatase) Test

The PAP test is a simple blood test, used to measure the amount of an enzyme—called prostatic acid phos­phatase (PAP)—that is produced by prostate epithelial cells and is abundant in seminal fluid (Kong 2013). Higher levels of PAP are associated with prostate cancer (Kong 2013). PAP deter­mination, in conjunction with PSA measurements, is useful in assessing the prognosis of prostate cancer. It is an important test, because it allows identification of prostate cancer patients who have an elevation of PAP, but not of PSA. This helps monitor the course of disease and response to treatment.

Baseline PAP 2

Freedom from prostate cancer recurrence at 5 years after prostate cancer surgery defined as psa>0.2 ng/mL

<0.4 U/liter


0.4-0.5 U/liter


>0.5 U/liter


Circulating Tumor Cells Assay

This test provides a measurement of cancer cells that have separated from a solid tumor site and are circulating in the bloodstream (Ligthart 2013). Detecting the pres­ence of circulating tumor cells in the blood has clinical usefulness in assessing the disease status and progno­sis of metastatic prostate cancer, and is predictive of overall survival (Miller 2010). Fasting prior to the blood draw is not required.


Transrectal Ultrasound

Transrectal ultrasound creates an image of the organs in the pelvis, and the most common indica­tion is for the evaluation of the prostate gland in men with elevated PSA levels, or with prostatic nodules on a digital rectal exam (UPMC 2013). Ultrasound clarifies the size of the prostate gland and aids in the distinction between benign prostate conditions and prostate cancer (UPMC 2013). This type of imaging can also be used to help guide a biopsy of the prostate (UPMC 2013).

Transrectal  ultrasound

Color Doppler Ultrasound

Color Doppler ultrasound is a medical imaging technique that is used to provide visualization of blood flow, using computer processing to add color to the image to greatly clarify what is happening inside the body (WebMD 2010). An ultrasound transducer is used to beam sound into the area of interest, and it reads the return­ing sound. When the sound bounces off a moving tar­get such as a blood vessel, the pitch changes as a result of the Doppler effect. The transducer can detect very subtle pitch changes, record them visually, and gen­erate an image showing where blood is flowing, and in what direction. Because a simple grayscale image can be a bit difficult to read, the ultrasound machine assigns different color values, depending on whether blood is moving towards or away from the transducer. In addition to showing the direction of flow, the col­ors also vary in intensity depending on the velocity of the flow, allowing doctors to also see how quickly the blood is moving (UPMC 2013).

A color Doppler ultrasound of a patient with a sus­pected tumor will reveal the precise areas where the velocity of blood flow is changing, mapping out the problem in full color (Fleischer 2000). This type of imaging can map out the tumor’s blood supply to clarify exactly how far the growth has spread (PCRI 2011). This can have an impact on what treatments are selected, and how surgery and other measures are approached. While color Doppler ultrasound can be done using a transducer on the out­side of the body, it can also be used for transrectal procedures, in which the probe is inserted to get a bet­ter view.

MRI (Magnetic Resonance Imaging)

The MRI has been used for over 30 years for pros­tate cancer detection and evaluation (Gupta RT 2013). In contrast to ultrasound imaging, prostate MRI has superior soft tissue resolution (UCCM 2013). Magnetic fields are used to locate and characterize prostate cancer. To do so, radiolo­gists use multi-parametric MRI, which includes four different types of MRI sequences (Gupta RT 2013). Currently, MRI is used to identify targets for prostate biopsy, and to make a surgical plan for men undergoing robotic pros­tatectomy. MRI imaging also helps surgeons decide whether to resect or spare the neurovascular bundle and assess surgical difficulty (Gupta RT 2013).

(Nuclear) Bone Scan

Prostate cancer can cause “hot spots” to appear on a bone scan if the cancer has metastasized to the bone (ACS 2013a; Tombal 2012). A bone scan for cancer uses nuclear tech­nology and involves administering a radioactive substance called a tracer to produce gamma radia­tion that can be picked up by a special camera (ACS 2013a). The tracer consists of radionuclides that bind to the bone and show up as dark or light spots. After the techni­cian injects the tracer, it usually takes between one and four hours for the radioactive substance to move throughout the skeleton. During this time, patients will be asked to drink up to six glasses of water to flush any tracer material not absorbed by bone. Then, the patient must remain still on a padded table while a large camera passes over the body.

A dark spot, also called a cold spot, might indicate lack of absorption of the tracer (ACS 2013a). This may also indi­cate that cancer has spread to the bone from the pros­tate gland. A normal scan shows evenly distributed tracer throughout the body. Risks associated with a bone scan are considered low, with a very small level of radiation exposure (ACS 2013a). The radionuclides injected into the bloodstream are excreted through the urine and have a low risk of toxicity (ACS 2013a).

Quantitative Computed Tomography (QCT)

Osteoporosis, or bone thinning, is associated with prostate cancer and can be a side effect of prostate cancer treatment (Tuck 2013). Quantitative computed tomogra­phy (QCT) is a highly sensitive test that is better able to determine bone density changes than common meth­ods such as DEXA testing (Smith 2001). Studies have shown that DEXA testing can often read degenerative changes involving bone and joint tissues and calcium deposits within blood vessels as bone density thus not suggest­ing osteoporosis when in fact bone loss is present (Bolotin 2001; Meirelles 1999; von der Recke 1996; AHRQ 2011). Quantitative computed tomography (QCT) is similar to other forms of computed tomography (CT). As with any CT scan, an X-ray tube and sensor rotate around the body area in a circular or spiral pattern, and a series of pictures are transmitted to a computer (Feretti 1999). The primary difference with QCT is the special analysis performed by special QCT software. While most computed tomog­raphy (CT) software produces a composite visual image to detect fractures or other symptoms in the scanned bone or soft tissue, QCT uses the data provided by the scanner to generate numerical values for the volume, mass, and density of bone (Feretti 1999). This allows QCT to distin­guish between cortical bone, which lines the outside of the bones, and trabecular bone, the softer tissue that makes up the center of the bone (IDI 2013). Trabecular bone is much more metabolically active than cortical bone—meaning, the two types of bone are replaced at different rates (IDI 2013). As a result, these two bone types can show dif­ferent rates of change in bone mineral density.

Genetic Testing

About half of US men diagnosed with prostate can­cer are classified as low-risk by use of conventional measures such as Gleason Score (a form of tumor grading), the prostate-specific antigen test (PSA), and a physical exam (Genomic Health 2013). Nonetheless, nearly 90% of these low-risk patients will choose to undergo immediate aggressive treatment such as radical prostatectomy or radiation even though there is less than a 3% chance of deadly progression (Genomic Health 2013).

A new test called Oncotype DX is now available to physicians and their patients. It measures the level of expression of 17 genes across four biological path­ways to predict prostate cancer aggressiveness (Genomic Health 2013).

Test results are reported as a Genomic Prostate Score (GPS) ranging from 0 to 100; this score is assessed along with other clinical factors to clarify a man’s risk prior to treatment intervention (Genomic Health 2013). This multi-gene test has been validated using the pros­tate needle biopsy sample taken before the prostate is removed, thereby providing the opportunity for low risk patients to avoid invasive treatments. According to the principle investigator of the validation study, individual biological information from the Oncotype DX prostate cancer test almost tripled the number of patients who can more confidently consider active surveillance and avoid unnecessary treatment and its potential side effects (Genomic Health 2013).

The advantage of this test for those who choose the comprehensive surveillance program utilized by Life Extension customers (which involves the use of several drugs, targeted nutrients, and adherence to healthy dietary patterns) is to provide greater assurance the right course of action is being followed.

For information about the Oncotype DX test, log on to

Prolaris® is another genomic test developed to aid physicians in predicting prostate cancer aggressive­ness in conjunction with clinical parameters such as Gleason score and PSA (Myriad 2013).

Prolaris® measures prostate cancer tumor biology at the molecular level. By measuring and analyzing the level of expression of genes directly involved with cancer replication, Prolaris® may be able to more accu­rately predict disease progression (Myriad 2013).

Prolaris® is a tool designed to measure the aggres­siveness of a patient’s cancers to better predict and stratify an individual’s relative risk of disease progres­sion within ten years (Myriad 2013). It may enable physicians to better define a treatment/monitoring strategy for their patients.

Prolaris® claims to be significantly more prognos­tic than currently used variables and provides unique additional information that can be combined with other clinical factors in an attempt to make a more accurate prediction of a patient’s cancer aggressive­ness and therefore disease progression (Myriad 2013).

Prolaris® has been shown to predict clinical pro­gression in four different clinical cohorts, in both pre and post-treatment scenarios.

In the treatment of prostate cancer, Prolaris® is prognostic at the point of diagnosis and in the post-surgery setting (Myriad 2013).

At diagnosis, Prolaris® can help to identify patients with less aggressive cancer who may be candidates for active surveillance. In addition, Prolaris® can define patients who appear clinically low-risk but have a more aggressive disease that requires more aggressive treatment.

Prolaris® testing is also well suited for use in post-prostatectomy patients that have higher risk features after surgery to better estimate their risk of disease recurrence and therefore adjust the level of monitor­ing or add additional therapy.

For more information about Prolaris®, log on to


Prostate cancer is the most common malignancy in US men (excluding non-melanoma skin cancer), afflicting one male in every six (Siegel 2012; PCF 2013b). A significant per­centage of men have underlying prostate cancer with­out even knowing it (Harvei 1999; Billis 1986; Sakr 1995).

These men have access to an arsenal of tools for their doctors to diagnose and then monitor the success or failure of various treatment modalities, including “active surveillance” or “watchful waiting.”

As you’ll learn in this protocol, one does not have to sit back and “watch” their PSA level steadily rise. Nutritional, hormonal, and drug approaches exist to help control early-stage, low-grade prostate tumors. There is data to support the efficacy of some of them as effective adjuvants in men with high-grade tumors as well (Gallardo-Williams 2004; Choi 2010; Dorai 2001; Fleshner 1999; Yang Y 2007; McCann 2008; von Holtz 1998; Zaidman 2007; Thirugnanam 2008).